Dushanbe, 18 March 2016 – Experts from the Netherlands involved in supporting national drug policies in Central Asia conducted an assessment mission to Tajikistan to identify national priorities and needs concerning drug strategies action plans and drug legislation.
This activity is supported within the sixth phase of the Central Asia Drug Action Programme (CADAP 6), funded by the European Union and implemented by a Consortium from the Netherlands, Czech Republic, Poland and Germany.
Central Asia Drug Action Programme (CADAP Phase 6) represents continuity of the EU policy and long term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction.
During the meetings with key government officials, EU experts presented experience on collaboration and coordination in drug policy in the Netherlands (and other EU countries). National partners made a presentation on findings from the survey report of 2010 “Analysis of the legislation in Tajikistan in the sphere of drug policy”. After the presentation, EU experts discussed with Tajik partners how to improve coordination and collaboration between national government agencies in drafting new drug strategies and laws and implementing existing legislation.
Within the framework of joint cooperation, EU experts and partners also reviewed the existing state of national development in drug strategies preparation, implementation and evaluation (with focus on the process and organisational structure of drug policy making) and in national reporting on the drug situation.